

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-32. (Cancelled)

33. (Currently Amended) A compound, which is  
4-ethoxy-6-fluoroquinoline-2-carboxylic acid;  
4-((E)-4-[(2-carboxy-6-fluoro-4-quinolinyl)oxy]-2-butenyl}oxy)-6-fluoroquinoline-2-  
carboxylic acid;  
6-fluoro-4-(3-methylbut-2-enyloxy)quinoline-2-carboxylic acid;  
4-[2-(3,4-dimethoxyphenyl)-2-oxo-ethoxy]-6-fluoroquinoline-2-carboxylic acid;  
methyl 4-(3-chloropropoxy)-6-fluoroquinoline-2-carboxylate; or  
methyl 4-(3-chloro-2-methylpropoxy)-6-fluoroquinoline-2-carboxylate; or  
a pharmaceutically acceptable salt thereof, or  
a tautomeric form, enantiomer, diastereoisomer or epimer thereof.

34. (Currently Amended) A compound according to claim 33, which is  
4-ethoxy-6-fluoroquinoline-2-carboxylic acid;  
4-((E)-4-[(2-carboxy-6-fluoro-4-quinolinyl)oxy]-2-butenyl}oxy)-6-fluoroquinoline-2-  
carboxylic acid;  
6-fluoro-4-(3-methylbut-2-enyloxy)quinoline-2-carboxylic acid;  
4-[2-(3,4-dimethoxyphenyl)-2-oxo-ethoxy]-6-fluoroquinoline-2-carboxylic acid;  
methyl 4-(3-chloropropoxy)-6-fluoroquinoline-2-carboxylate; or  
methyl 4-(3-chloro-2-methylpropoxy)-6-fluoroquinoline-2-carboxylate; or  
a pharmaceutically acceptable salt thereof.

35. (Currently Amended) A pharmaceutical composition, comprising a  
compound of claim 33 and a pharmaceutically acceptable carrier.

36. (Currently Amended) A pharmaceutical composition, comprising a  
compound of claim 34 and a pharmaceutically acceptable carrier.

37. (Currently Amended) A method for treating or preventing a hyperglycaemia-related pathology, which is diabetes, type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or hyperglycaemia, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 35.

38. (Currently Amended) A method according to claim 37, which is for treating diabetes, type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or hyperglycaemia.

39. (Currently Amended) A method for treating or preventing a hyperglycaemia-related pathology, which is diabetes, type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or hyperglycaemia, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 36.

40. (Currently Amended) A method according to claim 39, which is for treating diabetes, type II diabetes, dyslipidaemia, obesity, arterial hypertension, atherosclerosis, microangiopathy, macroangiopathy, retinopathy, neuropathy or hyperglycaemia.

41. (New) A compound according to claim 33, which is 4-ethoxy-6-fluoroquinoline-2-carboxylic acid; a pharmaceutically acceptable salt thereof, or a tautomeric form, enantiomer, diastereoisomer or epimer thereof.

42. (New) A compound according to claim 33, which is 4-((E)-4-[(2-carboxy-6-fluoro-4-quinolinyl)oxy]-2-butenyl}oxy)-6-fluoroquinoline-2-carboxylic acid; a pharmaceutically acceptable salt thereof, or a tautomeric form, enantiomer, diastereoisomer or epimer thereof.

43. (New) A compound according to claim 33, which is  
6-fluoro-4-(3-methylbut-2-enyloxy)quinoline-2-carboxylic acid;  
a pharmaceutically acceptable salt thereof, or  
a tautomeric form, enantiomer, diastereoisomer or epimer thereof.

44. (New) A compound according to claim 33, which is  
4-[2-(3,4-dimethoxyphenyl)-2-oxo-ethoxy]-6-fluoroquinoline-2-carboxylic acid;  
a pharmaceutically acceptable salt thereof, or  
a tautomeric form, enantiomer, diastereoisomer or epimer thereof.

45. (New) A compound according to claim 33, which is  
methyl 4-(3-chloropropoxy)-6-fluoroquinoline-2-carboxylate;  
a pharmaceutically acceptable salt thereof, or  
a tautomeric form, enantiomer, diastereoisomer or epimer thereof.

46. (New) A compound according to claim 33, which is  
methyl 4-(3-chloro-2-methylpropoxy)-6-fluoroquinoline-2-carboxylate,  
a pharmaceutically acceptable salt thereof, or  
a tautomeric form, enantiomer, diastereoisomer or epimer thereof.

47. (New) A method according to claim 37, which is for treating type II diabetes.

48. (New) A method according to claim 37, which is for treating hyperglycaemia.

49. (New) A method according to claim 37, which is for treating obesity.

50. (New) A method according to claim 37, which is for treating arterial hypertension.

51. (New) A method according to claim 37, which is for treating atherosclerosis.

52. (New) A method according to claim 37, which is for treating dyslipidaemia, microangiopathy, macroangiopathy, retinopathy or neuropathy.